MORPHOLOGICAL AND ULTRASOUND CHARACTERISTICS OF ENDOMETRIUM IN PATIENTS WITH BREAST CANCER AND THE RISK OF SECONDARY TUMORS
- Authors: Gerasimov AV1, Krasilnikov SE1, Kedrova AG2, Afonina NS2, Nechaeva OE2, Maksimenko TA3, Kosyi VV2
-
Affiliations:
- Новосибирский областной клинический онкодиспансер
- ФГБУ ФНКЦ ФМБА России
- Алтайский краевой онкодиспансера
- Issue: Vol 6, No 3 (2015)
- Pages: 39-47
- Section: Articles
- URL: https://journals.rcsi.science/clinpractice/article/view/8339
- DOI: https://doi.org/10.17816/clinpract6339-47
- ID: 8339
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
A V Gerasimov
Новосибирский областной клинический онкодиспансерврач Новосибирского областного клинического онкодиспансера
S E Krasilnikov
Новосибирский областной клинический онкодиспансерзав. отделением онкогинекологии Новосибирского областного клинического онкодиспансера
A G Kedrova
ФГБУ ФНКЦ ФМБА Россиизав. отделением онкологии ФНКЦ ФМБА России, д.м.н., профессор
N S Afonina
ФГБУ ФНКЦ ФМБА Россииначальник отдела ОМС ФНКЦ ФМБА России
O E Nechaeva
ФГБУ ФНКЦ ФМБА Россииврач ультразвуковой диагностики ФНКЦ ФМБА России
T A Maksimenko
Алтайский краевой онкодиспансера
V V Kosyi
ФГБУ ФНКЦ ФМБА Россииврач-онколог онкологического отделения ФНКЦ ФМБА России
References
- Kangaspeska S, Hultsch S, Edgren H, et.al. Re-analysis of RNA-Sequencing Data Reveals Several Additional Fusion Genes with Multiple Isoforms. PLoS ONE 7(10): e48745. doi: 10.1371/journal.pone.0048745
- Davies C, Pan H, Godwin J, et al; Adjuvant Tamoxifen. Longer Against Shorter (ATLAS) Collaborative Group: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013;381:805-816.
- Bernstein, L., Deapen, D., Cerhan, J.R., Schwartz, S. M., Liff, J., McGann-Maloney, E., et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 1999;91:1654-62.
- Bergman L., Beelen M.L., Gallee M.P., Hollema H., Benraadt J. et al. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres’ ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen. Lancet 2000; 356: 881-887.
- Goldstein, S.R. The effect of SERMs on the endometrium. Ann. N. Y. Acad. Sci 2001; 949:237-242
- Wickerham D.L., Fisher B., Wolmark N., Bryant J., Costantino J., Bernstein L., et al. Association of tamoxifen and uterine sarcoma. J Clin Oncol 2002; 20: 2758-60.
- Kim Mi-Jin, Kim Tae-Hee, Lee Hae-Hyeog, et al. G-protein Coupled Estrogen Receptor (GPER/ GPR30) and Women’s Health. J. Menopausal Med. 2015 Aug; 21(2): 79-81.
- Du G.Q., Zhou L., Chen X.Y., Wan X.P., and He, Y.Y. The G protein-coupled receptor GPR30 mediates the proliferative and invasive effects induced by hydroxytamoxifen in endometrial cancer cells. Biochem. Biophys Res Commun 2002;420: 343-49.
- Garuti G, Cellani F, Centinaio G, Sita G, Nalli G and Luerti M: Histopathologic behavior of endometrial hyperplasia during tamoxifen therapy for breast cancer. Gynecol Oncol. 2006;101:269-273.
- Berliere M, Charles A, Galant C and Donnez J: Uterine side effects of tamoxifen: a need for systematic pretreatment screening. Obstet Gynecol. 1998, 91:40- 44.
- Clarke R, Cook KL, Hu R, et al: Endoplasmic reticulum stress, the unfolded protein response, autophagy, and the integrated regulation of breast cancer cell fate. Cancer Res. 2012; 72:1321-1331. Endometrial cancer. Practice Bulletin No. 149. American College of Obstetricians and Gynecologists. Obstet Gynecol 2015;125:1006-26.
- Haas E, Bhattacharya I, Brailoiu E, et.al. Regulatory role of G protein-coupled estrogen receptor for vascular function and obesity. Circ Res. 2009 Feb 13;104(3):288-291.
- Бочкарева Н.В. Особенности метаболизма и рецепции эстрогенов при гиперпластических процессах и раке эндометрия. Автореферат дисс.. докт.мед.наук. Томск, 2007.
- Robert J. Kurman, Maria Luisa Carcangiu, C. Simon Herrington, Robert H. Young, (Eds.): WHO Classification of Tumours of Female Reproductive Organs. Tumours of the uterine corpus. IARC: Lyon 2014, p. 121-154.
- Plante B, Lessey В., Taylor R., et.al. G Protein-Coupled Estrogen Receptor (GPER) Expression in Normal and Abnormal Endometrium. J. Reproduction Science, 2012 Jul; 19(7): pp. 684-93.
- Knapp P, Chabowski A, Blachnio-Zabielska A, Walentowicz-Sadlecka M, Grabiec M, Knapp PA. Expression of estrogen receptors (alpha, beta), cyclo-oxygenase-2 and aromatase in normal endometrium and endometrioid cancer of uterus. Adv Med Sci 2013; 58:96-103.
- Prossnitz ER, Barton M. Estrogen biology: new insights into GPER function and clinical opportunities.Mol Cell Endocrinol 2014; 389: 71-83.
- Dedes J.K., Daniel Wetterskog, Alan Ashworth, Stan B. Kaye. Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol 2011;8:261-271.
- Smith HO, Leslie KK, Singh M, et.al. GPR30: a novel indicator of poor survival for endometrial carincinoma. Am J Obstet Gynecol. 2007 Apr; 196(4): 386. e1-9; discussion 386.e9-11.